Neuralstem, Inc. (NYSE MKT: CUR) today
published a blog post entitled “An ounce of
action is worth a ton of theory” on the Company’s website
which was republished on TheChairmansBlog.com.
President and CEO, Richard Garr, published a new blog about the
company’s Phase II ALS trial. In it, he writes about three areas in
which Neuralstem aims to make progress “…that will be essential
in pushing the cell therapy to a Phase III trial where [the company
hopes] to show efficacy in a statistically powered trial.”
patented technology enables the ability to produce neural stem cells
of the human brain and spinal cord in commercial quantities, and the
ability to control the differentiation of these cells constitutively
into mature, physiologically relevant human neurons and glia.
Neuralstem completed dosing of the last patient in an FDA-approved
Phase I safety clinical trial for amyotrophic lateral sclerosis
(ALS), often referred to as Lou Gehrig's disease, in August 2012; the
trial ends six months after that last surgery. Neuralstem has been
awarded orphan status designation by the FDA for its ALS cell
an exclusive, online media publication where publically and
privatively held firms alike share insights about their companies and
industries. TheChairmansBlog.com enables upper tier management to
discuss issues that are of importance to their stakeholders,
shareholders, and interested parties in an informal environment. In
addition to management`s insightful blog posts, TheChairmansBlog.com
staff and aggregate partners contribute articles on finance,
technology, health, and energy while providing updated market trends,
news, and information.
Leave a comment...